CVE:AQS

Aequus Pharmaceuticals Competitors

C$0.20

-0.01 (-4.76 %)

(As of 04/20/2021 09:37 AM ET)

Add

Compare

Today's Range

C$0.19

Now: C$0.20▼

C$0.20

50-Day Range

C$0.19

MA: C$0.22▼

C$0.28

52-Week Range

C$0.07

Now: C$0.20▼

C$0.29

Volume62,100 shs

Average Volume683,599 shs

Market CapitalizationC$26.19 million

P/E RatioN/A

Dividend YieldN/A

BetaN/A

Aequus Pharmaceuticals (CVE:AQS) Vs. HVT, EVE, SUGR, NU, LBL, and THCX

Should you be buying AQS stock or one of its competitors? Companies in the industry of "drug manufacturers - specialty & generic" are considered alternatives and competitors to Aequus Pharmaceuticals, including Harvest One Cannabis (HVT), Eve & Co Incorporated (EVE), SugarBud Craft Growers (SUGR), NeutriSci International (NU), Lattice Biologics (LBL), and (THCX.V) (THCX).

Aequus Pharmaceuticals vs. Harvest One Cannabis Stock

Aequus Pharmaceuticals (CVE:AQS) and Harvest One Cannabis (CVE:HVT) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, profitability, earnings, analyst recommendations, institutional ownership, dividends and valuation.

Analyst Recommendations

This is a summary of current recommendations and price targets for Aequus Pharmaceuticals and Harvest One Cannabis, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aequus Pharmaceuticals	0	0	0	0	N/A
Harvest One Cannabis	0	0	0	0	N/A

Valuation & Earnings

This table compares Aequus Pharmaceuticals and Harvest One Cannabis' revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aequus Pharmaceuticals	C$2.28 million	11.50	C$-2,880,394.00	C($0.02)	-9.09
Harvest One Cannabis	C$8.50 million	3.42	C$-89,908,156.00	C($0.36)	-0.32

Aequus Pharmaceuticals has higher earnings, but lower revenue than Harvest One Cannabis. Aequus Pharmaceuticals is trading at a lower price-to-earnings ratio than Harvest One Cannabis, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Aequus Pharmaceuticals and Harvest One Cannabis' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Aequus Pharmaceuticals	N/A	N/A	N/A
Harvest One Cannabis	N/A	N/A	N/A

Summary

Aequus Pharmaceuticals beats Harvest One Cannabis on 3 of the 5 factors compared between the two stocks.

Aequus Pharmaceuticals vs. Eve & Co Incorporated Stock

Aequus Pharmaceuticals (CVE:AQS) and Eve & Co Incorporated (CVE:EVE) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, profitability, earnings, analyst recommendations, institutional ownership, dividends and valuation.

Analyst Recommendations

This is a summary of current recommendations and price targets for Aequus Pharmaceuticals and Eve & Co Incorporated, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aequus Pharmaceuticals	0	0	0	0	N/A
Eve & Co Incorporated	0	0	0	0	N/A

Valuation & Earnings

This table compares Aequus Pharmaceuticals and Eve & Co Incorporated's revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aequus Pharmaceuticals	C$2.28 million	11.50	C$-2,880,394.00	C($0.02)	-9.09
Eve & Co Incorporated	C$2.84 million	3.35	C$-9,154,266.00	C($0.32)	-1.04

Aequus Pharmaceuticals has higher earnings, but lower revenue than Eve & Co Incorporated. Aequus Pharmaceuticals is trading at a lower price-to-earnings ratio than Eve & Co Incorporated, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Aequus Pharmaceuticals and Eve & Co Incorporated's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Aequus Pharmaceuticals	N/A	N/A	N/A
Eve & Co Incorporated	N/A	N/A	N/A

Summary

Aequus Pharmaceuticals beats Eve & Co Incorporated on 3 of the 5 factors compared between the two stocks.

Aequus Pharmaceuticals vs. SugarBud Craft Growers Stock

Aequus Pharmaceuticals (CVE:AQS) and SugarBud Craft Growers (CVE:SUGR) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, profitability, earnings, analyst recommendations, institutional ownership, dividends and valuation.

Analyst Recommendations

This is a summary of current recommendations and price targets for Aequus Pharmaceuticals and SugarBud Craft Growers, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aequus Pharmaceuticals	0	0	0	0	N/A
SugarBud Craft Growers	0	0	0	0	N/A

Valuation & Earnings

This table compares Aequus Pharmaceuticals and SugarBud Craft Growers' revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aequus Pharmaceuticals	C$2.28 million	11.50	C$-2,880,394.00	C($0.02)	-9.09
SugarBud Craft Growers	C$66,906.00	402.61	C$-962,178,924.00	C($1.79)	-0.03

Aequus Pharmaceuticals has higher revenue and earnings than SugarBud Craft Growers. Aequus Pharmaceuticals is trading at a lower price-to-earnings ratio than SugarBud Craft Growers, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Aequus Pharmaceuticals and SugarBud Craft Growers' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Aequus Pharmaceuticals	N/A	N/A	N/A
SugarBud Craft Growers	N/A	N/A	N/A

Summary

Aequus Pharmaceuticals beats SugarBud Craft Growers on 3 of the 5 factors compared between the two stocks.

Aequus Pharmaceuticals vs. NeutriSci International Stock

Aequus Pharmaceuticals (CVE:AQS) and NeutriSci International (CVE:NU) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, profitability, earnings, analyst recommendations, institutional ownership, dividends and valuation.

Analyst Recommendations

This is a summary of current recommendations and price targets for Aequus Pharmaceuticals and NeutriSci International, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aequus Pharmaceuticals	0	0	0	0	N/A
NeutriSci International	0	0	0	0	N/A

Valuation & Earnings

This table compares Aequus Pharmaceuticals and NeutriSci International's revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aequus Pharmaceuticals	C$2.28 million	11.50	C$-2,880,394.00	C($0.02)	-9.09
NeutriSci International	C$69,626.00	416.05	C$-1,982,032.00	C($0.01)	-14.62

NeutriSci International has lower revenue, but higher earnings than Aequus Pharmaceuticals. NeutriSci International is trading at a lower price-to-earnings ratio than Aequus Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Aequus Pharmaceuticals and NeutriSci International's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Aequus Pharmaceuticals	N/A	N/A	N/A
NeutriSci International	N/A	N/A	N/A

Summary

NeutriSci International beats Aequus Pharmaceuticals on 3 of the 5 factors compared between the two stocks.

Aequus Pharmaceuticals vs. Lattice Biologics Stock

Aequus Pharmaceuticals (CVE:AQS) and Lattice Biologics (CVE:LBL) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, profitability, earnings, analyst recommendations, institutional ownership, dividends and valuation.

Profitability

This table compares Aequus Pharmaceuticals and Lattice Biologics' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Aequus Pharmaceuticals	N/A	N/A	N/A
Lattice Biologics	N/A	N/A	N/A

Analyst Recommendations

This is a summary of current recommendations and price targets for Aequus Pharmaceuticals and Lattice Biologics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aequus Pharmaceuticals	0	0	0	0	N/A
Lattice Biologics	0	0	0	0	N/A

Valuation & Earnings

This table compares Aequus Pharmaceuticals and Lattice Biologics' revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aequus Pharmaceuticals	C$2.28 million	11.50	C$-2,880,394.00	C($0.02)	-9.09
Lattice Biologics	C$2.24 million	2.58	C$-2,436,142.00	C($0.02)	-2.37

Lattice Biologics has lower revenue, but higher earnings than Aequus Pharmaceuticals. Aequus Pharmaceuticals is trading at a lower price-to-earnings ratio than Lattice Biologics, indicating that it is currently the more affordable of the two stocks.

Summary

Lattice Biologics beats Aequus Pharmaceuticals on 3 of the 5 factors compared between the two stocks.

Aequus Pharmaceuticals vs. (THCX.V) Stock

Aequus Pharmaceuticals (CVE:AQS) and (THCX.V) (CVE:THCX) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, valuation, analyst recommendations, earnings, institutional ownership, risk and dividends.

Profitability

This table compares Aequus Pharmaceuticals and (THCX.V)'s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Aequus Pharmaceuticals	N/A	N/A	N/A
(THCX.V)	N/A	N/A	N/A

Analyst Ratings

This is a summary of current ratings and target prices for Aequus Pharmaceuticals and (THCX.V), as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aequus Pharmaceuticals	0	0	0	0	N/A
(THCX.V)	0	0	0	0	N/A

Valuation and Earnings

This table compares Aequus Pharmaceuticals and (THCX.V)'s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aequus Pharmaceuticals	C$2.28 million	11.50	C$-2,880,394.00	C($0.02)	-9.09
(THCX.V)	N/A	N/A	N/A	N/A	N/A

(THCX.V) has lower revenue, but higher earnings than Aequus Pharmaceuticals.

Summary

Aequus Pharmaceuticals beats (THCX.V) on 1 of the 1 factors compared between the two stocks.